Literature DB >> 10438839

Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.

A Fournillier1, E Depla, P Karayiannis, O Vidalin, G Maertens, C Trépo, G Inchauspé.   

Abstract

Interactive glycoproteins present on the surface of viral particles represent the main target of neutralizing antibodies. The ability of DNA vaccination to induce antibodies directed at such structures was investigated by using eight different expression plasmids engineered either to favor or to prevent interaction between the hepatitis C virus (HCV) envelope glycoproteins E1 and E2. Independently of the injection route (intramuscular or intraepidermal), plasmids expressing antigens capable of forming heterodimers presumed to be the prebudding form of the HCV envelope protein complex failed to induce any significant, stable antibodies following injection in mice. In sharp contrast, high titers of antibodies directed at both conformational and linear determinants were induced by using plasmids expressing severely truncated antigens that have lost the ability to form native complexes. In addition, only a truncated form of E2 induced antibodies reacting against the hypervariable region 1 of E2 (specifically with the C-terminal part of it) known to contain a neutralization site. When injected intraepidermally into small primates, the truncated E2-encoding plasmid induced antibodies able to neutralize in vitro the binding of a purified E2 protein onto susceptible cells. Because such antibodies have been associated with viral clearance in both humans and chimpanzees, these findings may have important implications for the development of protective immunity against HCV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438839      PMCID: PMC104276     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Sequence variation in hepatitis C viral isolates.

Authors:  A J Weiner; C Christopherson; J E Hall; F Bonino; G Saracco; M R Brunetto; K Crawford; C D Marion; K A Crawford; S Venkatakrishna
Journal:  J Hepatol       Date:  1991       Impact factor: 25.083

Review 2.  Protein folding in the cell.

Authors:  M J Gething; J Sambrook
Journal:  Nature       Date:  1992-01-02       Impact factor: 49.962

3.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

4.  Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.

Authors:  I Saito; T Miyamura; A Ohbayashi; H Harada; T Katayama; S Kikuchi; Y Watanabe; S Koi; M Onji; Y Ohta
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

8.  Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells.

Authors:  Y Matsuura; S Harada; R Suzuki; Y Watanabe; Y Inoue; I Saito; T Miyamura
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

Authors:  K Ishii; D Rosa; Y Watanabe; T Katayama; H Harada; C Wyatt; K Kiyosawa; H Aizaki; Y Matsuura; M Houghton; S Abrignani; T Miyamura
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

View more
  7 in total

1.  Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.

Authors:  J Satoi; K Murata; M Lechmann; E Manickan; Z Zhang; H Wedemeyer; B Rehermann; T J Liang
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Authors:  J M Heile; Y L Fong; D Rosa; K Berger; G Saletti; S Campagnoli; G Bensi; S Capo; S Coates; K Crawford; C Dong; M Wininger; G Baker; L Cousens; D Chien; P Ng; P Archangel; G Grandi; M Houghton; S Abrignani
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.

Authors:  Jing Jin; Jian-Ying Yang; Jing Liu; Yu-Ying Kong; Yuan Wang; Guang-Di Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

4.  Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.

Authors:  C Rollier; E Depla; J A R Drexhage; E J Verschoor; B E Verstrepen; A Fatmi; C Brinster; A Fournillier; J A Whelan; M Whelan; D Jacobs; G Maertens; G Inchauspé; J L Heeney
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.

Authors:  Li-Xin Zhu; Jing Liu; Ye Ye; You-Hua Xie; Yu-Ying Kong; Guang-Di Li; Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

6.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats.

Authors:  Mostafa K El-Awady; Ashraf A Tabll; Yasmine S El-Abd; Hassan Yousif; Mohsen Hegab; Mohamed Reda; Reem El Shenawy; Rehab I Moustafa; Nabila Degheidy; Noha G Bader El Din
Journal:  Virol J       Date:  2009-05-27       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.